文献速递疼痛医学术前评估与围术期医学

化疗诱导周围神经病变中慢性疼痛性及中重度神经病变的全球患病率:2000-2024年29国系统综述与Meta分析

Global estimates of prevalence of chronic painful neuropathy and moderate-to-severe neuropathy among patients with chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of data from 29 countries between 2000 and 2024.
PubMed 文献 · Reg Anesth Pain Med · 2025-12-04

结果显示合并患病率为47.76%(95%CI 37.50-58.08),异质性高(I²=97.45%),证据确定性极低。铂类和紫杉烷治疗者及乳腺癌、多发性骨髓瘤、肺癌患者患病率较高。

要点

  • CIPN患者中约47.76%报告慢性中重度或疼痛性神经病变。
  • 铂类和紫杉烷治疗者患病率分别为44.47%和55.68%。
  • 乳腺癌、多发性骨髓瘤和肺癌患者患病率较高(61.31%、53.55%、50.85%)。

核心结论

  • CIPN患者中慢性中重度或疼痛性神经病变的全球合并患病率为47.76%(95%CI 37.50-58.08),提示疾病负担显著。

主要发现

  • 合并患病率为47.76%(95%CI 37.50-58.08;95%预测区间24.68-71.84),异质性高(I²=97.45%;95%CI 97.15-97.72)。
  • 铂类和紫杉烷治疗者患病率分别为44.47%和55.68%。
  • 乳腺癌、多发性骨髓瘤和肺癌患者患病率分别为61.31%、53.55%和50.85%。
  • 研究设计、人类发展指数(HDI)和发表年份对患病率估计无显著调节作用。
  • 敏感性分析限制于明确测量疼痛性CIPN的研究(40.78%;95%CI 29.08-52.74)或中重度CIPN的研究(49.04%;95%CI 37.16-60.95),结果相似。

关键数值与推荐

  • GRADE评估证据确定性为“极低”。

临床怎么用

  • 应关注接受铂类或紫杉烷化疗及乳腺癌、多发性骨髓瘤、肺癌患者的慢性中重度或疼痛性CIPN筛查与管理。

局限性

  • 证据确定性极低,研究间异质性高(I²=97.45%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although the prevalence of chemotherapy-induced peripheral neuropathy (CIPN) has been reported, the proportion of patients with CIPN who report chronic moderate-to-severe neuropathy or chronic painful neuropathy remains poorly understood, despite its significant impact on patients' quality of life and treatment outcomes. METHODS: A systematic review and meta-analysis were conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The primary outcome was the pooled prevalence of chronic (≥3 months) moderate-to-severe CIPN or painful CIPN among patients diagnosed with CIPN. Estimates from each study were transformed using a double-arcsine transformation and pooled in a meta-analysis using an inverse variance heterogeneity model. Subgroup analysis was conducted based on geographical region, sex, chemotherapy regimen, primary cancer type, and funding source; metaregression analysis was conducted based on study design, human development index (HDI), and publication year. RESULTS: 76 studies from 29 countries, encompassing 13 635 patients with CIPN, were included. Among patients diagnosed with CIPN, the pooled prevalence of those reporting chronic moderate-to-severe CIPN or painful CIPN was estimated at 47.76% (95% CI 37.50 to 58.08; 95% prediction interval 24.68-71.84). Substantial heterogeneity was observed across studies (I²=97.45%; 95% CI for I 2 97.15 to 97.72). Subgroup analysis revealed that patients treated with platinum-based agents and taxanes had the highest prevalence of chronic moderate-to-severe CIPN or painful CIPN (44.47% and 55.68%, respectively), and among primary cancers, those with breast cancer, multiple myeloma, and lung cancer reported the highest prevalence of chronic moderate-to-severe CIPN or painful CIPN (61.31%, 53.55%, and 50.85%, respectively). Study design, HDI, and publication year were non-significant moderators of prevalence estimates. Based on our Grading of Recommendations, Assessment, Development, and Evaluation assessment, the certainty of evidence was considered "very low." Sensitivity analysis restricted to studies explicitly measuring painful CIPN (40.78%; 95% CI 29.08 to 52.74) or moderate-to-severe CIPN (49.04%; 95% CI 37.16 to 60.95) yielded similar prevalence estimates. CONCLUSION: This study provides the first comprehensive global estimate of the prevalence of chronic moderate-to-severe CIPN or painful CIPN, highlighting its significant burden on patients worldwide. The variation in prevalence across geographical regions, chemotherapy regimens, and primary cancers underscores the need for tailored management strategies and further research to address potential disparities.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. D'Souza RS, Saini C, Hussain N, et al. Global estimates of prevalence of chronic painful neuropathy and moderate-to-severe neuropathy among patients with chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of data from 29 countries between 2000 and 2024. Reg Anesth Pain Med. 2025. PMID: 39880412. doi:10.1136/rapm-2024-106229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。